|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CGRRF1 |
Gene summary for CGRRF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CGRRF1 | Gene ID | 10668 |
| Gene name | cell growth regulator with ring finger domain 1 | |
| Gene Alias | CGR19 | |
| Cytomap | 14q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q99675 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10668 | CGRRF1 | P74T-E | Human | Esophagus | ESCC | 1.94e-28 | 4.35e-01 | 0.1479 |
| 10668 | CGRRF1 | P75T-E | Human | Esophagus | ESCC | 1.83e-28 | 4.45e-01 | 0.1125 |
| 10668 | CGRRF1 | P76T-E | Human | Esophagus | ESCC | 1.66e-15 | 1.68e-01 | 0.1207 |
| 10668 | CGRRF1 | P79T-E | Human | Esophagus | ESCC | 5.28e-21 | 3.01e-01 | 0.1154 |
| 10668 | CGRRF1 | P80T-E | Human | Esophagus | ESCC | 7.15e-10 | 2.85e-01 | 0.155 |
| 10668 | CGRRF1 | P82T-E | Human | Esophagus | ESCC | 5.40e-13 | 4.44e-01 | 0.1072 |
| 10668 | CGRRF1 | P83T-E | Human | Esophagus | ESCC | 5.26e-10 | 2.76e-01 | 0.1738 |
| 10668 | CGRRF1 | P84T-E | Human | Esophagus | ESCC | 2.63e-12 | 4.36e-01 | 0.0933 |
| 10668 | CGRRF1 | P89T-E | Human | Esophagus | ESCC | 1.12e-05 | 2.41e-01 | 0.1752 |
| 10668 | CGRRF1 | P91T-E | Human | Esophagus | ESCC | 1.97e-07 | 7.21e-01 | 0.1828 |
| 10668 | CGRRF1 | P107T-E | Human | Esophagus | ESCC | 1.26e-18 | 2.65e-01 | 0.171 |
| 10668 | CGRRF1 | P127T-E | Human | Esophagus | ESCC | 1.36e-04 | 4.84e-03 | 0.0826 |
| 10668 | CGRRF1 | P128T-E | Human | Esophagus | ESCC | 1.20e-12 | 2.75e-01 | 0.1241 |
| 10668 | CGRRF1 | P130T-E | Human | Esophagus | ESCC | 2.60e-12 | 2.12e-01 | 0.1676 |
| 10668 | CGRRF1 | C04 | Human | Oral cavity | OSCC | 6.78e-07 | 4.63e-01 | 0.2633 |
| 10668 | CGRRF1 | C21 | Human | Oral cavity | OSCC | 1.29e-19 | 6.42e-01 | 0.2678 |
| 10668 | CGRRF1 | C30 | Human | Oral cavity | OSCC | 6.46e-14 | 7.29e-01 | 0.3055 |
| 10668 | CGRRF1 | C43 | Human | Oral cavity | OSCC | 4.63e-04 | 1.03e-01 | 0.1704 |
| 10668 | CGRRF1 | C46 | Human | Oral cavity | OSCC | 2.66e-14 | 3.99e-01 | 0.1673 |
| 10668 | CGRRF1 | C57 | Human | Oral cavity | OSCC | 2.02e-02 | 1.53e-01 | 0.1679 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
| GO:00303084 | Oral cavity | OSCC | negative regulation of cell growth | 101/7305 | 188/18723 | 2.85e-05 | 2.63e-04 | 101 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CGRRF1 | insertion | In_Frame_Ins | novel | c.679_680insTTCTAG | p.Gln227delinsLeuLeuGlu | p.Q227delinsLLE | Q99675 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| CGRRF1 | SNV | Missense_Mutation | novel | c.196N>C | p.Asn66His | p.N66H | Q99675 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CGRRF1 | SNV | Missense_Mutation | c.31N>A | p.Glu11Lys | p.E11K | Q99675 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGRRF1 | SNV | Missense_Mutation | novel | c.417G>T | p.Gln139His | p.Q139H | Q99675 | protein_coding | tolerated(0.06) | probably_damaging(0.99) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CGRRF1 | SNV | Missense_Mutation | c.206N>A | p.Gly69Asp | p.G69D | Q99675 | protein_coding | tolerated(0.05) | possibly_damaging(0.457) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CGRRF1 | SNV | Missense_Mutation | novel | c.368C>T | p.Pro123Leu | p.P123L | Q99675 | protein_coding | deleterious(0.02) | probably_damaging(0.942) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CGRRF1 | SNV | Missense_Mutation | novel | c.944C>A | p.Ser315Tyr | p.S315Y | Q99675 | protein_coding | tolerated(0.13) | benign(0.104) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CGRRF1 | SNV | Missense_Mutation | c.539C>T | p.Ala180Val | p.A180V | Q99675 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CGRRF1 | SNV | Missense_Mutation | novel | c.421N>C | p.Phe141Leu | p.F141L | Q99675 | protein_coding | tolerated(0.49) | benign(0.098) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CGRRF1 | SNV | Missense_Mutation | c.988N>G | p.Lys330Glu | p.K330E | Q99675 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |